Could a vaccine help fight Hard-to-Treat cancers?

NCT ID NCT07763301

Recruiting now Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental vaccine called YMN-136 in people with advanced liver, pancreatic, or biliary tract cancer that has progressed after standard treatment. The main goal is to check the vaccine's safety and find the best dose, while also seeing if it can help control the disease. Participants receive four vaccine injections about three weeks apart.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YMN-136 vaccine
What this could lead to: If successful, this vaccine could become a new treatment option to help control advanced liver, pancreatic, or biliary tract cancers.
What could go wrong: This is an early-phase trial with only 9 participants, so the vaccine may not work or could cause side effects. Its effectiveness is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms hepatocellular carcinoma liver cancer Liver Neoplasms malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER (BTC) LIVER CANCER PANCREATIC CANCER

Contacts and locations

Locations

West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.